Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, A.; Hurvitz, S.; Tolaney, S.; Loirat, D.; Punie, K.; Oliveira, Mafalda; Brufsky, A.; Sardesai, S.; Kalinsky, K.; Zelnak, A.; Weaver, R.; Traina, T.; Dalenc, F.; Aftimos, P.; Lynce, F.; Diab, S.; Cortés, J.; O’Shaughnessy, J.; Diéras, V.; Ferrario, C.; Schmid, P.; Carey, L.; Gianni, L.; Piccart, M.; Loibl, S.; Goldenberg, D.; Hong, Q.; Olivo, M.; Itri, L.; Rugo, H.

doi:10.1056/nejmoa2028485

Public

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Shared by NobleBlocks on Jan 1, 2021 • 12:00 AM UTC

Authors:

A. Bardia

S. Hurvitz

S. Tolaney

Abstract

Copyright © 2021 Massachusetts Medical Society. BACKGROUND Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!